Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia

被引:102
作者
Daskalopoulou, SS
Tzovaras, V
Mikhailidis, DP
Elisaf, M [1 ]
机构
[1] Univ Ioannina, Sch Med, Dept Internal Med, GR-45110 Ioannina, Greece
[2] Univ London, Royal Free & Univ Coll Med Sch, Royal Free Hosp, Dept Clin Biochem, London, England
关键词
uric acid; urate; uricosuric; fenofibrate; losartan; NSAID; diuretic; atorvastatin;
D O I
10.2174/138161205774913309
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Beyond allopurinol and the well-established uricosuric drugs, several other agents can decrease serum uric acid (SUA) levels, such as losartan, fenofibrate and some non-steroidal anti-inflammatory drugs (NSAIDs). Some of these drugs increase renal urate excretion. Hyperuricaemia and gout are common problems (at least 1% of Western men are affected by gout). Raised SUA levels increase the incidence of acute gout and renal calculi. Hyperuricaemia may also predict an increased risk of vascular events. Therefore, lowering SUA levels is of clinical relevance. In this review we consider the effect on SUA levels of drugs that are prescribed for indications other than treating hyperuricaemia. These drugs may obviate the need for specific treatment (e.g. allopurinol) aimed at lowering SUA levels. Furthermore, because hyperuricaemic patients may already be on several drugs (e.g. due to associated dyslipidaemia, hypertension and/or arthritis) compliance may be improved by avoiding additional medication. The potential for adverse effects associated with polypharmacy would also be decreased.
引用
收藏
页码:4161 / 4175
页数:15
相关论文
共 285 条
[121]   Consumption of cherries lowers plasma urate in healthy women [J].
Jacob, RA ;
Spinozzi, GM ;
Simon, VA ;
Kelley, DS ;
Prior, RL ;
Hess-Pierce, B ;
Kader, AA .
JOURNAL OF NUTRITION, 2003, 133 (06) :1826-1829
[122]  
JANNET D, 1994, OBSTET GYNECOL, V84, P354
[123]  
JELICIVANOVIC Z, 1985, CLIN CHEM, V31, P1141
[124]   EFFICACY AND TOLERANCE OF SPIRONOLACTONE IN ESSENTIAL-HYPERTENSION [J].
JEUNEMAITRE, X ;
CHATELLIER, G ;
KREFTJAIS, C ;
CHARRU, A ;
DEVRIES, C ;
PLOUIN, PF ;
CORVOL, P ;
MENARD, J .
AMERICAN JOURNAL OF CARDIOLOGY, 1987, 60 (10) :820-825
[125]   LONG-TERM METABOLIC EFFECTS OF SPIRONOLACTONE AND THIAZIDES COMBINED WITH POTASSIUM-SPARING AGENTS FOR TREATMENT OF ESSENTIAL-HYPERTENSION [J].
JEUNEMAITRE, X ;
CHARRU, A ;
CHATELLIER, G ;
DEGOULET, P ;
JULIEN, J ;
PLOUIN, PF ;
CORVOL, P ;
MENARD, J .
AMERICAN JOURNAL OF CARDIOLOGY, 1988, 62 (16) :1072-1077
[126]  
JOSSA F, 1994, J HUM HYPERTENS, V8, P677
[127]   Effect of atorvastatin on serum creatinine levels [J].
Kakafika, A ;
Liamis, G ;
Elisaf, M ;
Mikhailidis, D .
CURRENT MEDICAL RESEARCH AND OPINION, 2001, 17 (03) :230-231
[128]   Effect of atorvastatin on serum uric acid levels [J].
Kakafika, A ;
Tsimihodimos, V ;
Elisaf, M .
ATHEROSCLEROSIS, 2001, 158 (01) :255-255
[129]  
KAMILLI I, 1989, Z RHEUMATOL, V48, P307
[130]   A role for uric acid in the progression of renal disease [J].
Kang, DH ;
Nakagawa, T ;
Feng, LL ;
Watanabe, S ;
Han, L ;
Mazzali, M ;
Truong, L ;
Harris, R ;
Johnson, RJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (12) :2888-2897